Rabbit anti-CD39 Monoclonal Antibody

<strong>Rabbit anti-CD39 Monoclonal Antibody</strong>_x000D_ <strong>Catalog number:</strong> B2015601_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 10 µL_x000D_ <strong>Molecular Weight or Concentration:</strong> N/A_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> 2-8¬∞C_x000D_ <strong>Keywords:</strong> ectoapyrase;Ecto-apyrase;ecto-ATP diphosphohydrolase 1;ecto-ATPase 1;ecto-ATPDase 1;ectonucleoside triphosphate diphosphohydrolase 1;lymphoid cell activation antigen;NTPDase 1;NTPDase-1_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MŒ©-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Allard D, Allard B, Stagg J. On the mechanism of anti-CD39 immune checkpoint therapy J Immunother Cancer. 2020 Feb;8(1):e000186._x000D_ 2: Zhang H, Feng L, de Andrade Mello P, Mao C, Near R, Csizmadia E, Chan LL, Enjyoji K, Gao W, Zhao H, Robson SC. Glycoengineered anti-CD39 promotes anticancer responses by depleting suppressive cells and inhibiting angiogenesis in tumor models J Clin Invest. 2022 Jul 1;132(13):e157431._x000D_ 3: Perrot I, Michaud HA, Giraudon-Paoli M, Augier S, Docquier A, Gros L, Courtois R, D√©jou C, Jecko D, Becquart O, Rispaud-Blanc H, Gauthier L, Rossi B, Chanteux S, Gourdin N, Amigues B, Roussel A, Bensussan A, Eliaou JF, Bastid J, Romagn√© F, Morel Y, Narni-Mancinelli E, Vivier E, Paturel C, Bonnefoy N. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies Cell Rep. 2019 May 21;27(8):2411-2425.e9._x000D_ 4: Spatola BN, Lerner AG, Wong C, Dela Cruz T, Welch M, Fung W, Kovalenko M, Losenkova K, Yegutkin GG, Beers C, Corbin J, Soros VB. Fully human anti-CD39 antibody potently inhibits ATPase activity in cancer cells via uncompetitive allosteric mechanism MAbs. 2020 Jan-Dec;12(1):1838036._x000D_ 5: H√§usler SF, Del Barrio IM, Diessner J, Stein RG, Strohschein J, H√∂nig A, Dietl J, Wischhusen J. Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion Am J Transl Res. 2014 Jan 15;6(2):129-39. eCollection 2014._x000D_ 6: Correction: On the mechanism of anti-CD39 immune checkpoint therapy J Immunother Cancer. 2020 Jul;8(2):e000186corr1._x000D_ 7: Yan J, Li XY, Roman Aguilera A, Xiao C, Jacoberger-Foissac C, Nowlan B, Robson SC, Beers C, Moesta AK, Geetha N, Teng MWL, Smyth MJ. Control of Metastases via Myeloid CD39 and NK Cell Effector Function Cancer Immunol Res. 2020 Mar;8(3):356-367._x000D_ 8: Li XY, Moesta AK, Xiao C, Nakamura K, Casey M, Zhang H, Madore J, Lepletier A, Aguilera AR, Sundarrajan A, Jacoberger-Foissac C, Wong C, Dela Cruz T, Welch M, Lerner AG, Spatola BN, Soros VB, Corbin J, Anderson AC, Effern M, H√∂lzel M, Robson SC, Johnston RL, Waddell N, Smith C, Bald T, Geetha N, Beers C, Teng MWL, Smyth MJ. Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity Cancer Discov. 2019 Dec;9(12):1754-1773._x000D_ 9: Warren MC, Matissek S, Rausch M, Panduro M, Hall RJ, Dulak A, Brennan D, Das Yekkirala S, Koseoglu S, Masia R, Yang Y, Reddy N, Prenovitz R, Strand J, Zaidi T, Devereaux E, Foissac CJ, Stagg J, Lee BH, Holland P, Palombella VJ, Lake AC. SRF617 Is a Potent Inhibitor of CD39 with Immunomodulatory and Antitumor Properties Immunohorizons. 2023 May 1;7(5):366-379._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/33610376">10: Churov A, Zhulai G. Targeting adenosine and regulatory T cells in cancer immunotherapy Hum Immunol. 2021 Apr;82(4):270-278. </a>_x000D_ _x000D_ <strong>Products Related to Rabbit anti-CD39 Monoclonal Antibody can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>